Watch Ticker

Cullinan Oncology, Inc. Common Stock

Go to Cullinan Oncology, Inc. Common Stock Website

$8.02

0.08 (1.01%)

Live

Previous Close

$7.94

Day Range

$7.86 - $8.13

Previous Day Range

$7.52 - $8

Market Cap

$452.6 million USD

Day Vol.

112422

Previous Day Vol.

272441

Currency

USD

Primary Exchange

Nasdaq

Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. I...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

N/A - Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis

Cullinan Therapeutics received approval from the European Medicines Agency to initiate a Phase 1 trial of its bispecific CD19 T cell engager CLN-978 in patients with rheumatoid arthritis. The trial will be conducted at research institutions in Germany and Italy, and CLN-978 is also being studied for systemic lupus erythematosus.

Related tickers: CGEM.

Read Full Article

Cullinan Therapeutics, Inc. - Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Cullinan Therapeutics reported progress in its pipeline, including initial clinical data for CLN-978 in Systemic Lupus Erythematosus expected in Q4 2025 and positive results from the pivotal Phase 2b study of zipalertinib. The company ended 2024 with $606.9 million in cash, providing runway into 2028.

Related tickers: CGEM.

Read Full Article

Trending Tickers

Please sign in to view